|Bid||2.0300 x 0|
|Ask||2.0700 x 0|
|Day's Range||1.9900 - 2.1300|
|52 Week Range||0.4800 - 7.8400|
|Beta (5Y Monthly)||1.79|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar. 04, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.00|
Oncolytics Biotech® Announces Publication of Pelareorep's Clinical Benefit Against KRAS Mutated Colorectal Cancer
TORONTO , March 24, 2020 /CNW/ - Trading resumes in: Company: Oncolytics Biotech Inc. TSX Symbol: ONC Resumption (ET): 02:26:07 PM IIROC can make a decision to impose a temporary suspension (halt) of trading ...
SAN DIEGO, California and CALGARY, Alberta , March 24, 2020 /CNW/ -- Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced a favourable assessment from the Safety Committee following review of data from the window of opportunity study in early-stage breast cancer, known as AWARE-1. The Committee also approved an amendment of the study to reduce the dose of Tecentriq to be consistent with the currently approved breast cancer dose of 840mg. The study will continue to enroll patients and the Safety Committee will meet again for an additional pre-planned meeting.
SAN DIEGO and CALGARY, Alberta, March 5, 2020 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY - News) (TSX:ONC.TO - News), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced its financial results and operational highlights for the quarter and year ended December 31, 2019. "As we implemented our focused clinical development and investor relations strategies during 2019, our market valuation and trading volume experienced significant increases," said Kirk Look, Chief Financial Officer at Oncolytics. "During 2019, we successfully delivered on our strategy to engage pharma as we laid the groundwork for a catalyst rich 2020 and 2021," said Dr. Matt Coffey, President and CEO of Oncolytics Biotech.
During Q4 investors' call, Oncolytics (ONCY) is likely to provide an update on the studies of pelareorep, which is being developed for treating solid tumors and hematological malignancies.
SAN DIEGO and CALGARY, Alberta , Feb. 28, 2020 /CNW/ -- Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it will host a conference call for Analysts and Institutional Investors at 5:00 p.m. ET on Thursday , March 5, 2020 following release of its fourth quarter and year end 2019 financial results. Overseas callers should contact investor relations for the toll-free dial information for their country. A live webcast of the call will be accessible on the Investor Relations page of Oncolytics' website at www.oncolyticsbiotech.com and will be archived for three months.